Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.

Boon Piang Cher Sharon Goh Mohamed Ismail Abdul AzizGrace WongRaymond Ng Chee HuiBenjamin Shao-Kiat OngKwong-Hoe Ng

Published in: Expert review of pharmacoeconomics & outcomes research (2024)

At its current price, sacituzumab govitecan does not represent a cost-effective treatment for relapsed or refractory metastatic TNBC in Singapore. Our findings will be useful to inform funding decisions alongside other factors including clinical effectiveness, safety, and budget impact considerations.

Keyphrases

squamous cell carcinoma
small cell lung cancer
randomized controlled trial
systematic review
diffuse large b cell lymphoma
multiple myeloma
radiation therapy
hodgkin lymphoma
rectal cancer
locally advanced